At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint for survival, pathological complete response (pCR), in neoadjuvant studies.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement